// Global Analysis Archive
The source argues that Trump’s planned May 2026 China visit and a broader schedule of leader-level meetings could temporarily stabilise US–China relations by discouraging pre-summit escalation. It also warns that structural disputes—especially Taiwan arms sales and US election pressures—could drive renewed friction in the second half of 2026.
The reported delay of the Xi–Trump summit, officially attributed to the Iran conflict and the Strait of Hormuz crisis, also reflects deeper issues in pre-summit preparation and unresolved trade architecture proposals. The document suggests Beijing’s risk management over optics and entanglement, alongside Washington’s push for a managed-trade deliverable, contributed to a postponement with lowered expectations.
China has launched a major enforcement campaign against fentanyl precursor chemicals, reportedly including actions triggered by US anti-drug intelligence. Analysts cited in the source caution that progress on narcotics control may not translate into US concessions on broader disputes such as tariffs.
Trump’s abrupt postponement of a planned Beijing summit with Xi is assessed by analysts as reinforcing Beijing’s view of US unpredictability, even as China keeps public messaging restrained and channels open. The delay may give Beijing added leverage and preparation time while it resists perceived US pressure to support Hormuz security efforts without clear payoff.
MERICS’ Top China Risks 2026 argues Europe faces heightened exposure to US–China bilateral bargaining, tougher competitive and regulatory conditions for European firms, and persistent dependencies in critical materials and tech inputs. The report also highlights elevated Indo-Pacific military activity and domestic Chinese socio-economic pressures as factors that could increase external assertiveness and disruption risk.
The White House has announced US President Donald Trump will visit China from March 31 to April 2 for a summit with President Xi Jinping. Observers cited by the source suggest a US Supreme Court decision overturning Trump’s sweeping tariffs may reduce Washington’s leverage and shift the balance of negotiations.
The source argues that Trump’s planned May 2026 China visit and a broader schedule of leader-level meetings could temporarily stabilise US–China relations by discouraging pre-summit escalation. It also warns that structural disputes—especially Taiwan arms sales and US election pressures—could drive renewed friction in the second half of 2026.
The reported delay of the Xi–Trump summit, officially attributed to the Iran conflict and the Strait of Hormuz crisis, also reflects deeper issues in pre-summit preparation and unresolved trade architecture proposals. The document suggests Beijing’s risk management over optics and entanglement, alongside Washington’s push for a managed-trade deliverable, contributed to a postponement with lowered expectations.
China has launched a major enforcement campaign against fentanyl precursor chemicals, reportedly including actions triggered by US anti-drug intelligence. Analysts cited in the source caution that progress on narcotics control may not translate into US concessions on broader disputes such as tariffs.
Trump’s abrupt postponement of a planned Beijing summit with Xi is assessed by analysts as reinforcing Beijing’s view of US unpredictability, even as China keeps public messaging restrained and channels open. The delay may give Beijing added leverage and preparation time while it resists perceived US pressure to support Hormuz security efforts without clear payoff.
MERICS’ Top China Risks 2026 argues Europe faces heightened exposure to US–China bilateral bargaining, tougher competitive and regulatory conditions for European firms, and persistent dependencies in critical materials and tech inputs. The report also highlights elevated Indo-Pacific military activity and domestic Chinese socio-economic pressures as factors that could increase external assertiveness and disruption risk.
The White House has announced US President Donald Trump will visit China from March 31 to April 2 for a summit with President Xi Jinping. Observers cited by the source suggest a US Supreme Court decision overturning Trump’s sweeping tariffs may reduce Washington’s leverage and shift the balance of negotiations.
| ID | Title | Category | Date | Views | |
|---|---|---|---|---|---|
| RPT-3291 | Summitry as Shock Absorber: Trump’s Second-Term China Strategy and the Late-2026 Risk Window | US-China relations | 2026-03-30 | 0 | ACCESS » |
| RPT-3012 | Why the Xi–Trump Beijing Summit Slipped: War-Time Optics, Managed-Trade Gaps, and Fraying Prep Work | US-China relations | 2026-03-23 | 0 | ACCESS » |
| RPT-2893 | Beijing Signals Goodwill with Fentanyl-Precursor Crackdown Ahead of Possible Trump Visit | US-China relations | 2026-03-20 | 0 | ACCESS » |
| RPT-2818 | Beijing Calibrates Response as Trump Delays Xi Summit Amid Iran War and Hormuz Pressure Signals | US-China relations | 2026-03-18 | 0 | ACCESS » |
| RPT-117 | Europe’s 2026 China Risk Outlook: Strategic Marginalization, Supply-Chain Chokepoints, and Rising Indo-Pacific Volatility | China | 2025-09-09 | 1 | ACCESS » |
| RPT-1466 | Trump-Xi Summit Set for March 31–April 2 as Tariff Ruling Reshapes Negotiating Terrain | US-China relations | 2024-08-23 | 0 | ACCESS » |